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Abstract
Background: Outcomes in observational studies may not best estimate those expected in the HIV vaccine efficacy
trials. We compared retention in Simulated HIV Vaccine Efficacy Trials (SiVETs) and observational cohorts drawn from
two key populations in Uganda.
Methods: Two SiVETs were nested within two observational cohorts, one in Fisherfolk (FF) and another one in Female
Sex Workers (FSW). Adult participants in each observational cohort were screened for enrolment into SiVETs. Those
screened-out or not screened continued participation in the observational (non-SiVET) cohorts. SiVET participants were
administered a licensed hepatitis B vaccine in a schedule that mimicked an actual HIV vaccine efficacy trial. Both cohorts
were followed for 12 months and retention was assessed through dropout, defined as lost to follow up, being
uncontactable, refusal to continue or missing the last study clinic visit. Dropout rates were compared using Poisson
models giving rate ratios and 95% confidence intervals (95%CI).
Results: Out of 1525 participants (565 FF and 960 FSW), 572 (38%) were enrolled into SiVETs (282-FF and 290-FSW), and
953 (62%) remained in the non-SiVET cohorts. Overall, 326 (101 SiVET, 225 non-SiVET) dropped out in 1260 Person Years
of Observation (PYO), a dropout rate of 25.9 /100 PYO (95%CI: 23.2–28.8); fewer dropped out in the SiVET cohorts (18.4,
95% CI: 15.1–22.4) than in the non-SiVET cohorts (31.6, 95% CI: 27.8–36.1), rate ratio (RR) =0.58, 95% CI: 0.46–0.73. In all
cohorts, the dropout was more marked in FSW than in FF population. Duration lived in community was associated with
dropout in both SiVETs and religion in both non-SiVET cohorts.
Conclusion: The rate of dropout was lower in SiVET compared to non-SiVET cohort. Though the difference in dropout
between SiVET and non-SiVET was generally similar, the actual dropout rates were higher in the FSW population.
Conduct of SiVETs in these key populations could mean that designing HIV Vaccine Efficacy Trials will benefit from
lower dropout rate shown in SiVET than non-SiVET observational cohort.
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Background
Populations with high HIV incidence and good retention in
follow up are needed to ensure successful conduct of
efficacy trials of the HIV vaccines being developed [1]. In
countries, where the general population HIV incidence is
low [2, 3] to be used for this purpose, sub populations such
as key populations could be a better alternative. However,
key populations are perceived to be highly unstable and dif-
ficult to keep in follow up [4–7]. Observational cohorts in
key populations in Africa have shown high HIV incidence
[8–13] but slightly lower study completion (70–76%) [9,
13–15] than in the general population (85%) [3]. Attrition
from studies could bias the estimate of outcome measures
and diminish statistical power. Estimation of expected trial
attrition is an important component of trial planning to
avoid the risk of type II error or higher expense and uneth-
ical concern of following up more than the necessary num-
ber of trial participants.
Contrary to perception that Fisherfolks (FF) on the
shoreline of Lake Victoria and Female sex workers (FSW)
in Kampala, Uganda are highly mobile populations and
hard to maintain in follow up [6, 16], these populations
could be suitable for HIV vaccine efficacy trials. Studies in
these key populations have demonstrated very high HIV
incidence of 3 to 11 per 100 person years [8, 9, 11, 12, 14,
15], willingness to participate > 90% [17, 18] and relatively
good retention in follow up > 75% [6, 9, 19, 20].
To date, no HIV efficacy trials have completed follow up
in these populations and the available information comes
from observational cohorts. Studies have shown how dif-
ferences in the selection of participants into a trial affects
HIV incidence compared to observational cohorts in the
same populations [8, 21–23] but we do not know how the
dropout rate would compare under similar settings. During
the conduct of efficacy trials, participants are seen more
regularly and techniques such as phone call reminders and
home visits are employed to keep participants in follow up.
This level of attention is likely to be higher than that in
observational cohorts and could improve adherence to
clinic attendance as well as completion of trial procedures
beyond what is seen in observational cohorts. Therefore,
planning HIV vaccine efficacy trials in key populations as-
suming the same dropout rate seen in observational data
could be misleading. Inaccurate information on dropout
rates predicted at trial planning stage could result in an
over or under estimate of the study sample size, resulting
in either unnecessary cost or diminished statistical power
for the outcome. Accurate information on attrition in the
FF and FSW populations is needed to inform the design of
HIV vaccine efficacy trials in these and similar populations.
In this paper we use data from two Simulated Vaccine Effi-
cacy Trials (SiVETs) nested within observational cohorts in
the FF and FSW populations in Uganda to (i) compare the
dropout rates in the SiVET (interventional) cohorts to that
in the non-SiVET (observational) cohorts, (ii) report rea-
sons for dropout and (iii) determine factors associated with
dropout.
Methods
Design and setting
The data used in this paper were obtained from two obser-
vational cohorts. Observational cohort one (OBC1) was in
the FF population, from January 2012 to April 2015 at
MRC/UVRI and LSHTM Uganda Research Unit clinic lo-
cated in Masaka town about 100 km West of Kampala, the
capital of Uganda. OBC1 recruited from fishing communi-
ties located on the shoreline of Lake Victoria in Masaka
district. Houses in the fishing communities are mainly
made of wattle-and-mud or iron sheeting, and concen-
trated on the edge of swamps. While the main economic
activity is fishing, there are small-scale businesses and
services supporting the fishing occupation and the cohort
was recruited from all occupations.
The second observational cohort (OBC2) was in the
FSW population in Kampala, April 2008 to April
2017.The cohort of FSW was established at a clinic
located on Mengo hill, about 2 km from Kampala city
center. This cohort (OBC2) recruited women from the
city’s sex work hot spots, including clusters of bars,
nightclubs, lodges and guesthouses. Both cohorts de-
tails have been previously described [8, 11, 14, 20, 24].
SiVET cohort
Two Simulated Vaccine Efficacy Trials were nested
within the observational cohorts. SiVET1 (FF), in the FF
communities, ran from June 2012 until April 2014.
SiVET2 (FSW), in the FSW cohort, ran from August
2014 until April 2017. The SiVETs used a hepatitis B
vaccine as a proxy for an HIV vaccine, with the aim of
assessing acceptability of vaccination and retention in a
future HIV vaccine trial environment. Cohort partici-
pants who had been enrolled for 3 to 18 months were
consecutively screened for eligibility (Table 1) and
enrolled until the required sample size was accrued.
Those enrolled were administered a licensed Hepatitis B
vaccine (ENGERIX-BTM GlaxoSmithKline Biologicals
Rixensart, Belgium) following the standard schedule of
0, 1 and 6months, under conditions that mimicked a
possible HIV vaccine efficacy trial. In addition to the
vaccination visits, participants in the SiVET cohort were
followed up every 3 months for 12 months in line with
the source observational cohort objective of determining
HIV status every quarter.
Non-SiVET cohort
Participants in OBC1 and OBC2 that screen failed
SiVETs eligibility (Table 1), and those that were not
screened because SIVET enrolment was complete, but
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fulfilled the criteria (Table 1) for continuing follow up in
OBC1 (FF) and OBC2 (FSW), remained in follow up in
the respective OBCs in the SiVET concurrent period,
forming non-SiVET1 (FF) cohort in OBC1 and non-
SiVET2 (FSW) cohort in OBC2. Participants in the non-
SiVET cohort were followed up every 3 months for 12
months in the SiVET concurrent period (Fig. 1).
Retention strategies
SIVET cohorts At the onset of the SiVET cohorts, each
participant provided a cell phone number, and add-
itionally a physical contact address and phone contact
of a neighbor or someone who could easily reach
them any time. This information was checked at each
follow up clinic visit. Study field staff reminded par-
ticipants of their next scheduled clinic visits using
their cell phone at least 2 days before a scheduled
clinic visit and visited their physical location the day
after the scheduled visit if they did not attend. Partic-
ipants who needed help to access the clinic were
offered transport.
Non-SiVET cohorts At the onset of the non-SIVET co-
horts, each participant provided a cell phone contact
number. This information was checked at each follow
up clinic visit. When a participant missed a scheduled
clinic visit the study field staff contacted him/her by
cell phone and encouraged clinic attendance.
Definitions
Study completion For the purpose of this paper, we
defined study completion as a participant completing 12
months of follow up in the non-SiVET or SiVET cohorts
concurrent period, or until HIV infection, or being with-
drawn from a given cohort for any of the following reasons;
reaction to hepatitis B vaccine, pregnancy (SiVETs only),
being at low risk of HIV infection (non-SiVET1 only) and
investigator discretion.
Lost to follow-up This was defined as missing at least
two sequential follow up clinic visits.
Dropout This was defined as either lost to follow up,
participant being uncontactable, refusal to continue or
missing the 12-month study clinic visit.
Primary outcomes in this paper This analysis compares
the rate of dropout between SiVET and non-SiVET co-
horts in the 12months of SiVET concurrent period, re-
ports the main reasons for dropping out, and investigates
factors associated with dropout in each cohort.
Statistical methods
The data collected in the non-SiVET cohorts were man-
aged in MS Access, 2003 (Microsoft Corporation, Red-
mond, WA), while data from the SiVET cohorts were
managed in OpenClinica 3.5 (Waltham, MA). We summa-
rized participant characteristics using counts and percent-
age and compared them between non-SIVET and SiVET
Table 1 SiVETs and non-SiVETs cohorts’ participant eligibility criteria
SiVET cohorts non-SiVET cohorts
Inclusion
• At least 3 and no more than 18 months of follow up in the OBC1 or OBC2
• HIV-1 negative and willing to undergo HIV testing
• Aged ≥18 years and≤ 49 years
• Able and willing to provide written informed consent
• Able and willing to provide adequate locator information including physical
address
• Willing and able to return for follow-up clinic visits
• Intending to reside in study area for at least one year
Females only
• Willing to undergo pregnancy testing
• Not breastfeeding and no intent for pregnancy in the next one year
• Willing to use effective contraception during the study and at least 3 months after
the last vaccination
Inclusion
• At least 3 months and no more than 18months of follow
up in OBC1 or OBC2
• Still in follow up in the OBCs
• HIV-1 negative and willing to undergo HIV testing
Exclusion Exclusion
• HIV positive
• History of severe allergic reaction to any substance
• An acute or chronic illness
• Contraindication for Hepatitis B vaccine
• Participation in another clinical trial
• Hepatitis B exposure, as assessed by surface antigen (HBsAg) and core antibody
(HBcAb) titers (only SiVET2)
• Not willing to provide written consent
HIV positive
SiVET- Simulated Vaccine Efficacy Trial, OBC- Observational cohort
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cohorts in the respective key population using chi-square
tests. Participants who enrolled into either study and did
not return for any follow up visit were given an arbitrary
follow-up time of 1 week to allow inclusion in regression
models. The dropout rate was estimated as the number of
people who dropped out divided by the total person years
of observation (PYO), expressed as a rate per 100 PYO.
PYO were estimated as sum of the time from enrolment
into SiVET to the date of SiVET completion or censoring.
In the non-SiVET cohort, PYO were estimated as sum of
time from the date SiVET began enrolment, ending on
the date of the last SiVET participant clinic visit or date
of censoring. Unadjusted rate ratios (uRR) and adjusted
rate ratios (aRR) and their 95% confidence intervals
(CI) were used to find factors associated with dropout
by fitting Poisson regression models. Bivariable analysis
was performed initially. Multivariable analysis was per-
formed, including all variables which caused a change
in the rate of more than 20%, except for sex and age
which were included a priori.
Results
Screening and enrolment
In total 3828 participants were screened for possible en-
rolment into observational cohorts before SiVET rollout
and 2622 (69%) were enrolled, Fig. 1. The main reasons
for screen failure were non-involvement in sex work
(n = 612), being at low risk for HIV infection (n = 337)
and HIV infection (n = 215). At the time of introduction
of the SiVET protocol, 1525 (58%) of the participants
enrolled into observational cohorts before SiVETs were
eligible for screening into SiVETs. The main reasons for
ineligibility were having spent more than 18 months in
observational cohorts (n = 930) and exiting observational
cohorts before SiVET protocol roll out (n = 121), Fig. 1.
Of the 1525 eligible for screening, 672 (44%) were con-
secutively screened and 572 (85%) of these enrolled into
SiVETs (282 from FF and 290 from FSW). The main
reason for screening but not enrolling into SiVETs was
exposure to Hepatitis B (n = 52) (assessed as shown in
Table 1). In total, 953 (283 from FF and 670 from FSW)
Fig. 1 Study profile for participants screened and enrolled in observational cohorts before SiVET, in the non-SiVET and SiVET cohorts in the key
populations, Uganda 2012–2017. *Low HIV risk defined as having protected sex with ≥one or new sexual partner, no history of STIs, non-use of
illicit drugs and /or alcohol and not being away from home for ≥2 nights per/week, £HIV counselling and Testing
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participants were eligible for follow up in the non-SiVET
cohorts in the SiVET concurrent period, Fig. 1.
Baseline participant characteristics
FF
Compared to non-SiVET1 cohort, SiVET1 cohort had more
men 73% vs 48% and more participants aged ≥35 years,
24% vs 14%, Table 2. Furthermore, non-SiVET1 cohort had
more participants without any education 12% vs 6%, work-
ing in restaurant/bar/hair salon occupation 23% vs 8% and
lived at the current location for 1 year or less 34% vs 17%,
Table 2.
FSW
Compared to the non-SiVET2 cohort, SiVET2 cohort had
fewer participants aged ≥35 years, 12% vs 22%, Baganda
tribe 44% vs 53% and those working in restaurant/bar/hair
salon occupation 29% vs 38% Table 2. Additionally, the
non-SiVET2 cohort had more participants without any
education 41% vs 6%, single never married 36% vs 24%
and those that lived at the current location for zero to one
year 33% vs 18%, Table 2.
Primary outcome (study dropout)
Among the 1525 participants, 326 (21%) dropped out of
the cohorts. Of these 225/953 (24%) dropped out of the
non-SiVET cohorts compared to 101/572 (18%), p = 0.01
in the SiVET cohorts.
Dropout rates
Overall, 326 participants dropped out of cohorts in 1260
Person Years of Observation (PYO), a dropout rate of
25.9 /100 PYO, 95%CI:23.2–28.8. The dropout rate was
higher in the non-SiVET cohorts 31.6, 95%CI: 27.8–36.1
compared to SiVET cohorts 18.4, 95%CI: 15.1–22.4, rate
ratio (RR) =0.6, 95%CI: 0.5–0.7, Table 3. Stratifying the
dropout rate by the study populations, it was still higher
in the non-SiVET cohort compared to SiVET cohort in
a given population but generally, the dropout rate was
highest in the FSW population, Table 3.
Similarly, comparing dropout rates by similar partici-
pant characteristics, the rates were generally higher in
non-SiVET cohorts, except for participants that had
lived at the current location for zero to 1 year in the
SiVET2 cohort, Table 4.
Reasons for dropping out of cohorts
Of the 225 participants that dropped out of non-SiVET
cohorts, 89 (40%) were lost to follow up other reasons
are shown in Fig. 1. Similarly, of 101 participants that
dropped out of the SiVET cohorts, 31 (31%) were lost to
follow up, Fig. 1.
Factors associated with dropout
FF
Factors independently associated with dropout in the non-
SiVET1 cohort included sex [female: adjusted rate ratio
(aRR) = 0.5, 95%CI: 0.3–0.9)], religion [Muslim: 0.4 (0.2–
0.8)], occupation [work in restaurant/bar/hair salon:
3.1(1.3–7.4) compared to being engaged in small-scale busi-
ness], other factors are shown in Table 5. In SiVET1 cohort,
only duration lived at the current location [> 1 year: 0.5
(0.3–0.9)] was independently associated with dropout.
FSW
Factors independently associated with dropout in the
non-SiVET2 cohort included religion [Muslim: 0.6 (0.3–
0.9)], marital status [married: 2.2 (1.1–5.6) compared to
single never married] and having sex under influence of
alcohol [sometimes: 0.4 (0.2–0.8) compared to never]. In
SiVET2 cohort, factors independently associated with
dropout included age [25–34 years: 0.6 (0.3–0.9), 35 or
more years: 0.3 (0.1–0.7) all compared to 18–24 years]
and duration lived at the current location [> 1 year: 0.4
(0.2–0.7)], other factors are shown in Table 5.
Discussion
We investigated how participant dropout rate from the
Simulated HIV Vaccine Efficacy Trial (SiVET) differs
from the observational cohort within which SiVET was
nested. We compared participant dropout rate in SiVET
to that in non-SiVET cohort adjusted to align over a set
duration of time in two distinct key populations in
Uganda. We found that the dropout rate in the SiVET
cohort was nearly half that in the non-SiVET cohort.
When stratified by the study population, the difference
in dropout rate between SiVET and non-SiVET cohorts
was generally similar though the dropout rates in either
cohort were higher in the FSW population.
The results of this comparative analysis suggest that
even when participants are drawn from the same popu-
lation and followed up for the same duration of time,
the selection criteria into efficacy trial and/or trial envir-
onment could cause a difference in trial dropout rate.
Much as the observational cohorts were the recruitment
source for the SiVETs, participants who joined SiVETs
differed in significant ways from those who did not.
SiVET recruited fewer females, young participants (< 25
years), not educated, working in restaurants/bar/hair
salon, single and never married and those that had lived
at the current location for a shorter duration (1 year or
less). These participant characteristics have been previ-
ously associated with high attrition from observational
cohorts in these [9, 11, 15] and other populations [25,
26]. Furthermore, these participant characteristics have
also been previously associated with high risk of HIV
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Table 2 Baseline characteristics of the participants in the non-SiVET and SiVET cohorts in FF and FSW populations in Uganda 2012–
2017
Variables FF(N = 565) FSW(N = 960)
non-SiVET1
(n = 283)
SiVET1
(n = 282)
p -value non-SiVET2
(n = 670)
SiVET2 (n = 290) p-value
Total (%) Total (%) Total (%) Total (%)
Sex < 0.01 na
Male 137 (48) 205 (73) na na
Female 146 (52) 77 (27) 670 (100) 290 (100)
Age group (years) 0.01 < 0.01
18–24 127 (45) 88 (31) 304 (45) 85 (29)
25–34 115 (41) 127 (45) 289 (43) 143 (49)
35+ 41 (14) 67 (24) 77 (12) 62 (22)
Tribe 0.02 0.04
Baganda 114 (40) 128 (45) 295 (44) 153 (53)
Banyankole 50 (18) 31 (11) 109 (16) 32 (11)
Banyarwanda 69 (24) 54 (19) 40 (6) 20 (7)
Other 50 (18) 69 (25) 226 (34) 85 (29)
Education 0.04 < 0.01
None 35 (12) 19 (6) 272 (41) 16 (6)
Primary 190 (67) 211 (75) 282 (42) 149 (51)
Secondary+ 58 (21) 52 (19) 116 (17) 125 (43)
Marital status 0.17 0.01
Single never married 86 (30) 84 (30) 240 (36) 68 (24)
Married 125 (44) 143 (51) 42 (6) 18 (6)
Single ever married 72 (26) 55 (19) 388 (58) 204 (70)
Religion 0.86 0.96
Christian 216 (76) 217 (77) 507 (76) 219 (76)
Muslim 67 (24) 65 (23) 163 (24) 71 (24)
Occupation < 0.01 0.02
Fishing/fish relatedb 124 (44) 169 (60) 0 (0) 0 (0)
Small scale business 59 (21) 73 (26) 17 (3) 11 (4)
Work in restaurant/bar/hair salon 65 (23) 23 (8) 196 (29) 111 (38)
Sex work 0 (0) 0 (0) 452 (67) 165 (57)
Othera 35 (12) 17 (6) 5 (1) 3 (1)
Duration lived at the current location (years) < 0.01 < 0.01
0–1 96 (34) 48 (17) 222 (33) 51 (18)
> 1 187 (66) 234 (83) 448 (67) 239 (82)
Illicit drug use 0.29 0.79
No 254 (90) 245 (87) 132 (20) 55 (19)
Yes 29 (10) 37 (13) 538 (80) 235 (81)
SiVET- Simulated Vaccine Efficacy Trial, N-Total sample size, n-Sub study sample size, %-Percent, na- Not applicable, p-value compares SiVET to non-SiVET stratified
by population
aPeasant farmer, house wife
bDrying fish, salting or smoking fish
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acquisition in these populations [9, 15, 16, 19] and other
HIV at-risk populations [27, 28].
SiVET cohorts’ lower dropout rate could also be at-
tributable to the enhanced follow up procedures. SiVET
cohorts’ participants were reminded of their next sched-
uled clinic visit at least 2 days in advance, and were
picked by a trial staff on a motor cycle or vehicle if they
needed help to access the clinic for their visits. Enhanced
strategies to keep participants in follow up have been
previously associated with high retention in follow up
[29]. Furthermore, SiVET participants had four more
clinic visits to complete trial procedures and adherence
counselling. Regular study clinic visits have been associ-
ated with improved study outcomes and completion
[30]. More clinic visits resulted in more HIV risk reduc-
tion counselling and other free Health care services in
the SiVET cohort than non-SIVET cohort and a lower
HIV incidence observed in this group [8].
The results suggest a number of factors were inde-
pendently associated with dropout from the SiVET and
non-SiVET cohorts including age, gender, occupation,
marital status, duration lived at the current location,
having sex while drunk, having multiple sexual partners,
mobility, condom use with a new sexual partner, and
genital sores/ulcer disease. These have previously been
associated with more non-study completion in the key
populations [6, 15, 20, 27, 31] and other populations [3,
32]. A surprising finding was that in FF and FSW non-
SiVET cohorts, the rate of dropout among Muslims was
statistically significantly lower than that among Chris-
tians. Though not statistically significant, a similar result
was observed in the SiVET cohorts. While there is no
clear explanation to this, Muslims have been indicated
to be less likely to migrate [33] and over 90% of the
dropouts were either uncontactable, lost to follow up or
missed the last visit.
The commonest reasons for dropping out of the
SiVET and non-SiVET cohorts were lost to follow up,
being uncontactable and missing the last visit without
giving investigators an opportunity to ascertain the ac-
tual reasons. Missing study visits has been associated
with migration [11, 34]. Similarly, participants that mi-
grate have been previously associated with increased risk
of HIV infection because of high-risk sexual behaviours
among those that move [11, 34]. SIVET cohort recruited
more of the participants that had lived at the current lo-
cation for more than 1 year. This could partly explain
the lower drop out observed in SiVET cohort in this
analysis and the lower HIV incidence in SiVET previ-
ously published [8]. Recruitment strategies aimed at
avoiding participants that move could improve retention
but screen out those likely to seroconvert. Therefore, re-
searchers planning HIV vaccine efficacy trials in these
populations need strategies aimed at retaining partici-
pants likely to be mobile, to minimize dropout rates and
maximize HIV incidence.
Our study strengths included large sample size, two dis-
tinct key populations, aligning both SiVET and non-
SiVET cohorts to the same duration of follow up in a con-
current period and participants being seen by the same
study staff. Furthermore, participants were allowed a run
in period of at least 3 months participation in the source
cohort, mimicking a screening enrolment time lag in an
actual HIV vaccine efficacy trial. Results from SiVETs sug-
gest that with enhanced strategies, these populations could
be enrolled and retained in HIV vaccine efficacy trials.
The limitations of this comparative analysis include,
SiVET cohorts were likely to screen and enroll partici-
pants that came on time for their three - eighteen
months visit in the source cohort. This could have fil-
tered participants likely to come on time and complet-
ing study follow up visits beyond that seen in non-
SiVET cohorts. This could have inadvertently decreased
dropout in SiVETs compared to non-SiVET cohorts.
Furthermore, although participants screened for HIV
vaccine efficacy trials are required to have a run in
period before actual recruitment, as it was done in
SiVETs, it is unlikely that this will be up to three to
eighteen months. The procedures in the SiVET and
non-SiVET cohorts were conducted by the same study
staff and were not blinded. This could have led to dif-
ferential handling of follow up efforts to ensure that
participants return for follow up. SiVET cohort partici-
pants were fully informed that the vaccine being ad-
ministered has no effect on their risk of HIV infection
but prevents against Hepatitis B infection. This could
have led to participants continued attendance to enjoy
enhanced health care services. Nonetheless, in an actual
Table 3 Dropout in non-SIVET and SIVET cohorts, FF and FSW populations, Uganda 2012–2017
Population non-SiVET SiVET Rate ratio (95%CI)
C/PYO Rate-R2 (95%CI) C/PYO Rate-R1 (95%CI) R1/ R2
FF 93/335 27.8 (22.7–34.0) 46/322 14.3 (10.7–19.0) 0.51 (0.37–0.71)
FSW 132/376 35.1 (29.6–41.6) 55/227 24.2 (18.6–31.6) 0.69 (0.50–0.96)
Overall 225/711 31.6 (27.8–36.1) 101/549 18.4 (15.1–22.4) 0.58 (0.46–0.73)
FF- Fisherfolk, FSW -Female sex worker, C- cases of dropout, PYO- person years of observation, SiVET- Simulated Vaccine Efficacy Trial
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HIV vaccine efficacy trial, participants have to be
informed that the vaccine being administered is not yet
known to prevent against HIV infection. Even with
these limitations, our comparative analysis gives a rare
opportunity of estimating dropout rate in trials nested
within source cohorts adjusting them to reflect the
same duration of follow up in the same period and
populations.
Table 4 Dropout by participant characteristics in the non-SiVET and SiVET cohorts in FF and FSW populations, Uganda 2012–2017
Variables FF(N = 565) FSW(N = 960)
non-SiVET1 (n = 283) SiVET1 (n = 282) non-SiVET2 (n = 670) SiVET2 (n = 290)
Total (%) C/PYO Rate C/PYO Rate Total (%) C/PYO Rate C/PYO Rate
Sex
Male 342 (60) 47/165 28.6 32/236 14.6 – – – – –
Female 223 (40) 46/170 27.0 14/86 16.2 960 (100) 132/376 35.1 55/227 24.2
Age group (years)
18–24 215 (38) 45/150 30.0 16/103 15.6 389 (41) 66/162 40.9 22/64 34.4
25–34 242 (43) 35/135 26.0 25/144 17.3 432 (45) 52/163 31.9 27/111 24.3
35+ 108 (19) 13/50 26.0 5/75 6.7 139 (14) 14/52 27.0 6/52 11.6
Tribe
Baganda 242 (43) 43/128 33.7 22/146 15.0 448 (47) 58/177 32.8 30/118 25.4
Banyankole 81 (14) 17/62 27.3 4/36 11.2 141 (15) 25/60 41.7 5/26 19.6
Banyarwanda 123 (22) 20/86 23.1 6/62 9.7 60 (6) 8/19 42.1 5/16 31.5
Other 119 (21) 13/59 22.1 14/78 17.9 311 (32) 41/120 34.1 15/67 22.3
Education
None 54 (9) 12/32 38.0 2/23 8.7 288 (30) 54/151 35.7 3/11 27.6
Primary 401 (71) 64/229 27.9 34/241 14.1 431 (45) 56/157 35.7 30/118 25.4
Secondary+ 110 (20) 17/74 22.9 10/58 17.3 241 (25) 22/68 32.3 22/98 22.4
Marital status
Single never married 170 (30) 33/97 34.1 19/99 19.2 308 (32) 52/132 39.5 11/58 18.9
Married 268 (47) 39/151 25.8 20/160 12.5 60 (6) 11/24 46.1 5/12 40.9
Single ever married 127 (23) 21/87 24.1 7/63 11.1 592 (62) 69/221 31.2 39/157 24.9
Religion
Christian 433 (77) 78/244 32.0 35/247 14.1 726 (76) 106/277 38.3 42/170 24.7
Muslim 132 (23) 15/91 16.4 11/75 14.7 234 (24) 26/99 26.2 13/57 22.7
Occupation
Fishing/fish relatedb 293 (52) 42/151 27.7 24/193 12.4 – – –
Small scale business 132 (23) 14/73 19.1 15/82 18.1 28 (3) 3/13 23.0 1/9 10.8
Work in restaurant/bar/hair salon 88 (16) 31/61 50.5 5/27 18.6 307 (32) 35/118 29.6 19/87 21.7
Sex work – – – – – 617 (64) 93/243 38.3 34/128 26.6
Othera 52 (9) 6/49 12.2 2/19 10.6 8 (1) 1/2 44.4 1/2 44.0
Duration lived at the current location (years)
0–1 144 (25) 38/104 36.7 13/53 24.4 273 (28) 41/129 31.8 19/37 51.2
> 1 421 (75) 55/231 23.8 33/269 12.3 687 (72) 91/247 36.8 36/190 19.0
Illicit drug use
No 499 (88) 84/298 28.1 38/278 13.7 187 (20) 31/63 49.5 8/43 18.6
Yes 66 (12) 9/37 24.6 8/44 18.1 773 (80) 101/314 32.2 47/184 25.5
FF -Fisherfolk, FSW- Female sex worker, C- cases of dropout, PYO- person years of observation, SiVET- Simulated Vaccine Efficacy Trial
aPeasant farmer, house wife
bDrying fish, salting or smoking fish
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Conclusion
In conclusions, HIV Vaccine Efficacy Trial’s inclusion-
exclusion criteria and possibly some degree of bias in pro-
cedures, selected volunteers with characteristics different
from those in the source population and not recruited.
These in combination with trial environment and en-
hanced retention strategies reduced dropout rate from a
trial in mobile populations. In HIV high-risk populations
where no HIV prevention or simulation trials have been
previously conducted to provide data for planning HIV
vaccine efficacy trials, the dropout rate in observational
cohort could be a useful tool. However, this rate might
have to be decreased by 40% as observed in the SiVET co-
horts in these key populations. Evidence further suggests
that the decrease in dropout varied by population, 50% in
FF and 30% in FSW. Entire results from these studies sug-
gest that FF and FSW could be good populations for
actual HIV vaccine efficacy trials because of the already
known high HIV incidence and lower dropout rates in a
trial setting as seen in the SiVETs.
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